Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
about
Bile acid transportersPharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal ImpairmentNew insights in bilirubin metabolism and their clinical implicationsThe role of inflammation in cholestasis: clinical and basic aspectsOxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathwayIdentification of a functional antioxidant response element within the eighth intron of the human ABCC3 geneUpregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodentsEnhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPSClinical application of transcriptional activators of bile salt transporters.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsNuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.Concept on the pathogenesis and treatment of primary biliary cirrhosisBile formation and secretion.Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene.Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid responseOATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in miceBenefit of farnesoid X receptor inhibition in obstructive cholestasis.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.Swertianlarin, isolated from Swertia mussotii Franch, increases detoxification enzymes and efflux transporters expression in rats.An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.Oral administration of oleanolic acid, isolated from Swertia mussotii Franch, attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats.Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstructionRegulation of hepatic ABCC transporters by xenobiotics and in disease states.New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-sThe ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXRMechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.Nuclear receptors as drug targets in cholestatic liver diseases.Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes.Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signalingCompensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice.Nuclear receptors as therapeutic targets in cholestatic liver diseases.Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.
P2860
Q24652624-DA84AB3F-EA99-4F8B-9EA1-4B81425875D8Q26751452-9A241BBA-A662-4436-8C38-CC6F41738B6DQ26863145-5FB20797-00E3-4F99-9D2A-FD555271E656Q27694662-455C7B72-EAEA-4F64-B598-6C84BEF807A4Q28238852-7049625B-135D-47A9-876A-EFB68FE04979Q28250453-B78207E1-57BB-4848-A9E0-98A4D88A37B4Q28292663-5856F16F-202A-4C67-86E6-6E8F42D52EFEQ28565596-6C650E37-1CF4-4974-A18E-EA7BE55DD885Q33709930-FB13246C-4578-4AFF-B6C3-FC3584B1D6A0Q33763177-5CF6064E-2610-41F3-B455-981192DCD7BCQ33838275-CC28DF30-2906-40FE-920B-0EB5177A98B5Q33866454-7A9C59CB-9481-40CC-B476-E5648426415FQ33881922-429A8481-1030-4B56-BC73-EB21309D9DCBQ34287166-7B3FAD29-D04D-41CB-B771-7B99552629F1Q34382931-FC849F1B-8F70-43D7-9383-EE7B603045CBQ34438127-4F153F52-EEE1-42FB-B5B3-4A74528DFAE8Q34552485-5F50DF48-47A0-44D8-B976-521887325F73Q34854093-56B3E25F-0D56-4004-85F7-B2721155A4D9Q34983994-E75D6569-30F9-4652-BF1F-0B0218ED4A68Q34990717-75BB4C61-1533-4520-96B1-16C32F6DD251Q35145151-46BD39C2-5391-4261-A139-78EB15C390BAQ35206374-E0F7F204-98F4-442C-A5DE-C237673BDC38Q35479252-FC00A3E6-1362-47AC-8DE6-9DC3666634BEQ35583781-357A0133-50B7-4AAC-9CAE-55C414AB45D6Q35690177-A64C1360-29E3-4E4B-A451-D528B72FF48BQ35741546-A398CFC1-45B8-46B6-BD5C-3B6791F4EF09Q35815498-9412F722-CB0F-4260-929C-9C98F3DB5D1CQ35956193-10A8A9FA-C4CD-4B5D-9AA4-38B2CEC7EC9AQ36173223-EB222EA6-72AF-4BCC-8FA9-6B29C5DC9A21Q36606886-AD332954-65E5-4DB3-AA5A-21542CF54FF6Q36776615-0FACC761-7ED3-4FC7-9429-94D4E92ED411Q36786270-E2431498-5FC5-4ACD-B492-E05DE2C51091Q36852518-66DF514A-82B0-446E-84A3-FE6D9AB5C2F2Q36919924-2537B6BE-2C34-41E2-8832-53992F1A1739Q37021320-C779AD7A-B938-4E9A-9F73-9002436117E2Q37130129-D5C9136F-7BA9-46BD-8BEC-2D2EA3D12288Q37148632-078E8176-C9FB-412C-BE94-356CA6722072Q37227362-72C938AE-0A43-42E9-BE48-48DDDD05332BQ37230857-0EF4478E-62D8-4BFD-A43E-C6C6CBAA6ED4Q37291393-B1A2BA37-4624-47C0-84BC-C92BB612C375
P2860
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@en
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@nl
type
label
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@en
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@nl
prefLabel
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@en
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@nl
P2093
P50
P1476
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.
@en
P2093
Andrea Fuchsbichler
Dagmar Silbert
Hanns Ulrich Marschall
Helmut Denk
Michael Trauner
P304
P356
10.1016/S0168-8278(03)00096-5
P577
2003-06-01T00:00:00Z